Analysis of Biochemical and Virological Efficacy of Human Lymphoblastoid Interferon (IFN) in Patients with Compensated Type C Liver Cirrhosis |
| |
| Authors: | Haruhide Shinzawa Yutaka Yoshida Osamu Masamune Takayoshi Toyota Tsuneo Takahashi Reiji Kasukawa Toshinori Sudo Kazuyoshi Ishikawa Masafumi Komatsu Motoyasu Ishii Toru Takagi Sigeru Hisamichi Syunichi Sato Humihiro Ichida |
| |
| Affiliation: | (1) Second Department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan;(2) First Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan;(3) First Department of Internal Medicine, Akita University School of Medicine, Akita, Japan;(4) Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan;(5) Second Department of Internal Medicine, Fukushima Medical School, Fukushima, Japan;(6) First Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan;(7) Department of Internal Medicine, Fukushima Red Cross Hospital, Fukushima, Japan;(8) Department of Public Health, Tohoku University School of Medicine, Sendai, Japan;(9) Niigata University School of Medicine, Niigata, Japan |
| |
| Abstract: | A controlled trial was conducted to compare the efficacy of interferon (IFN) between two groups of patients with type C liver. Thirty-five patients were randomly assigned to group A (17 patients) or group B (18 patients). The former received 3 megaunits (MU) of human lymphoblastoid IFN six days per week for two weeks, followed by three days per week for 50 weeks; the latter group received 6 MU six days per week for two weeks followed by three days per week for 24 weeks. The percentages of biological sustained responders (B-SR) and virological sustained responders (V-SR) were 29.4 and 23.5%, respectively, in group B, and 17.6% for both in group A. The therapeutic effects were not different between two groups. HCV genotype 2 accounted for significantly higher percentage of B-SR and V-SR (both 57.1%, respectively). These findings indicate that IFN is effective in type C cirrhosis with genotype 2. |
| |
| Keywords: | hepatitis C virus liver cirrhosis interferon HCV-RNA, HCV genotype HCV-RNA levels |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
